Ensol Biosciences Inc. Logo

Ensol Biosciences Inc.

AI-driven biopharma developing peptide drugs for unmet medical needs.

140610 | KO

Overview

Corporate Details

ISIN(s):
KR7140610007
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노10로 51(탑립동), 대전광역시

Description

Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-02-16 00:00
전환사채(해외전환사채포함)발행후만기전사채취득 (제1회차)
Korean 9.0 KB
2024-01-10 00:00
주식등의대량보유상황보고서(약식)
Korean 129.6 KB
2023-12-15 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2023-12-14 00:00
기타주요경영사항(자율공시)(코스닥시장 상장을 위한 상장예비심사청구 철회의 건)
Korean 4.7 KB
2023-11-13 00:00
임상시험단계진입ㆍ종료(자율공시)(항암제 병용 치료제 카리스1000(C1K) 제1상 임상시험 종료)
Korean 9.0 KB
2023-10-20 00:00
기업설명회(IR)개최결과
Korean 6.6 KB
2023-10-10 00:00
기업설명회(IR)개최
Korean 7.1 KB
2023-07-10 00:00
주식등의대량보유상황보고서(약식)
Korean 110.7 KB
2023-05-31 00:00
임상시험단계진입ㆍ종료(자율공시)(골관절염 치료제 엔게디1000(E1K) 제1b상 임상시험 종료)
Korean 13.8 KB
2023-03-29 00:00
정기주주총회결과
Korean 18.8 KB
2023-03-21 00:00
사업보고서 (2022.12)
Korean 989.3 KB
2023-03-14 00:00
주주총회소집공고
Korean 78.2 KB
2023-03-14 00:00
의결권대리행사권유참고서류
Korean 84.9 KB
2023-03-10 00:00
감사보고서제출
Korean 9.4 KB
2023-03-08 00:00
주주총회소집결의
Korean 12.4 KB

Automate Your Workflow. Get a real-time feed of all Ensol Biosciences Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ensol Biosciences Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ensol Biosciences Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.